Lupin Lines Up A Pair Of US Launches
Droxidopa Generic Of Northera Follows Launch Of Rival To Horizon’s Duexis
India’s Lupin has launched its droxidopa rival to Northera in the US, in 100mg, 200mg and 300mg strengths. The company also launched the generic version of Horizon’s Duexis ibuprofen/famotidine 800mg/26.6mg tablets.
You may also be interested in...
Having previously seen patent litigation with originator Chiesi dismissed, Lupin has realized plans to launch the first UK generic version of Fostair (beclometasone/formoterol), with the potential significant cost savings” for the UK’s National Health Service.
Adamis has announced receiving FDA approval for Zimhi, its high-dose naloxone hydrochloride for injection, indicated for the treatment of opioid overdose. The company has partnered with US WorldMeds to market Zimhi by the first quarter of 2022.
US-based Phlow and Fresenius Kabi have announced an alliance to supply essential medicines, including injectables, for public health emergencies and to Children’s Hospital Coalition, a project by Phlow. In an exclusive interview with Generics Bulletin, Phlow chief business officer Dan Hackman talks about the partnership, addressing US supply chain disruptions, domestic manufacturing and more.